BioSpace News Archive

iTeos Therapeutics, Inc. announced a poster presentation of preclinical data on EOS-984, a potential first-in-class small molecule inhibitor targeting the equilibrative nucleoside transporter 1 in oncology, at the American Association for Cancer Research Annual Meeting, being held April 5-10, 2024 in San Diego, California.

Affini-T Therapeutics, Inc. announced that management is presenting data from the company’s oncogenic driver programs targeting HLA-A*11:01 KRAS G12D and HLA-A*02:01 p53 R175H at this year’s American Association for Cancer Research Annual Meeting 2024 in San Diego.

Replimune Group, Inc. announced the presentation of interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid organ or hematopoietic cell transplants, by Michael R. Midgen, M.D., of the University of Texas MD Anderson Cancer Center during an oral session at the AACR 2024 Annual Meeting in San Diego.

Laekna announced that the company has presented two internally-discovered preclinical candidates, in addition to a poster presentation on a clinical trial, at the 2024 Annual Meeting of the American Association for Cancer Research in San Diego, California.

Renalys Pharma, Inc. announced that it has submitted an Investigational New Drug Application for sparsentan to the Pharmaceuticals and Medical Devices Agency for a Phase III clinical trial in Japan.

Arrowhead Pharmaceuticals, Inc. presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran in patients with severe hypertriglyceridemia.

Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, shared the full data from two posters highlighting advancements across two distinct modalities presented at the 2024 American Association for Cancer Research Annual Meeting, held April 5-10 in San Diego, CA.

Regeneron Pharmaceuticals, Inc. announced the oral plenary session presentation of positive pivotal data from the Phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma at the American Association for Cancer Research Annual Meeting 2024 in San Diego.

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines, announced the publication of positive safety, immunogenicity, and efficacy data from the full cohort of patients enrolled in its GT-30 clinical trial in Nature Medicine.

Edgewood Oncology announced the publication of new preclinical data from a study of BTX-A51 in human liposarcoma conducted by Dana-Farber Cancer Institute and Hebrew University-Hadassah Medical School to be presented at the AACR Annual Meeting 2024 in San Diego.